CliffBio
biologic

prolastin,prolastin-c,prolastin-c liquid

Alpha-1-Proteinase Inhibitor (Human)

Loss of exclusivityMarch 2032projected — 12-year biologic exclusivity estimate
CompanyGrifols →View the full company profile on CliffBio

Drug detail

Brand nameprolastin,prolastin-c,prolastin-c liquid
Active ingredientAlpha-1-Proteinase Inhibitor (Human)
Strength500MG/10ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2020
Marketing statusRx

More from Grifols

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

prolastin,prolastin-c,prolastin-c liquid patent cliff — loss of exclusivity March 2032 | CliffBio